Disease Biomarkers in Multiple Sclerosis: Current Serum Neurofilament Light Chain Perspectives

References

• Thompson AJ , BaranziniSE, GeurtsJ, HemmerB, CiccarelliO. Multiple sclerosis. Lancet, 391(10130), 1622–1636 (2018).
   PubMed Web of Science ®Google Scholar
• Zivadinov R , JakimovskiD, GandhiSet al. Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert. Rev. Neurother., 16(7), 777–793 (2016).
   PubMed Web of Science ®Google Scholar
• Fuchs TA , CarolusK, BenedictRHBet al. Impact of focal white matter damage on localized subcortical gray matter atrophy in multiple sclerosis: a 5-year study. AJNR Am. J. Neuroradiol., 39(8), 1480–1486 (2018).
   PubMed Web of Science ®Google Scholar
• Eshaghi A , PradosF, BrownleeWJet al. Deep gray matter volume loss drives disability worsening in multiple sclerosis. Ann. Neurol., 83(2), 210–222 (2018).
   PubMed Web of Science ®Google Scholar
• Tavazzi E , ZivadinovR, DwyerMGet al. MRI biomarkers of disease progression and conversion to secondary-progressive multiple sclerosis. Expert Rev. Neurother., 20(8), 821–834 (2020).
   PubMed Web of Science ®Google Scholar
• Khalil M , TeunissenCE, OttoMet al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol., 14(10), 577–589 (2018).
   PubMed Web of Science ®Google Scholar
• Gafson AR , BarthelemyNR, BomontPet al. Neurofilaments: neurobiological foundations for biomarker applications. Brain, 143(7), 1975–1998 (2020).
   PubMedGoogle Scholar
• Carare RO , Bernardes-SilvaM, NewmanTAet al. Solutes, but not cells, drain from the brain parenchyma along basement membranes of capillaries and arteries: significance for cerebral amyloid angiopathy and neuroimmunology. Neuropathol. Appl. Neurobiol., 34(2), 131–144 (2008).
   PubMed Web of Science ®Google Scholar
• Khalil M , SalzerJ. CSF neurofilament light: a universal risk biomarker in multiple sclerosis?Neurology, 87(11), 1068–1069 (2016).
   PubMed Web of Science ®Google Scholar
• Kuhle J , BarroC, AndreassonUet al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and SiMoA. Clin. Chem. Lab. Med., 54(10), 1655–1661 (2016).
   PubMed Web of Science ®Google Scholar
• Hendricks R , BakerD, BrummJet al. Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood. Bioanalysis, 11(15), 1405–1418 (2019).
   PubMed Web of Science ®Google Scholar
• Bridel C , Van WieringenWN, ZetterbergHet al. Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol., 76(9), 1035–1048 (2019).
   PubMed Web of Science ®Google Scholar
• Dalla Costa G , MartinelliV, SangalliFet al. Prognostic value of serum neurofilaments in patients with clinically isolated syndromes. Neurology, 92(7), e733–e741 (2019).
   PubMed Web of Science ®Google Scholar
• Disanto G , AdiutoriR, DobsonRet al. Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. J. Neurol. Neurosurg. Psychiatry, 87(2), 126–129 (2016).
   PubMed Web of Science ®Google Scholar
• Bittner S , SteffenF, UphausTet al. Clinical implications of serum neurofilament in newly diagnosed MS patients: a longitudinal multicentre cohort study. EBioMedicine, 56, 102807 (2020).
   PubMed Web of Science ®Google Scholar
• Manouchehrinia A , StridhP, KhademiMet al. Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology, 94(23), e2457–e2467 (2020).
   PubMed Web of Science ®Google Scholar
• Barro C , BenkertP, DisantoGet al. Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis. Brain, 141(8), 2382–2391 (2018).
   PubMedGoogle Scholar
• Jakimovski D , ZivadinovR, RamanthanMet al. Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: a longitudinal retrospective 5-year study. Mult. Scler., 26(13),1670–1681 (2020).
   PubMed Web of Science ®Google Scholar
• Thebault S , AbdoliM, FereshtehnejadSM, TessierD, Tabard-CossaV, FreedmanMS. Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis. Sci. Rep., 10(1), 10381 (2020).
   PubMed Web of Science ®Google Scholar
• Anderson V , BentleyE, LovelessSet al. Serum neurofilament-light concentration and real-world outcome in MS. J. Neurol. Sci., 417, 117079 (2020).
   PubMed Web of Science ®Google Scholar
• Kuhle J , NourbakhshB, GrantDet al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology, 88(9), 826–831 (2017).
   PubMed Web of Science ®Google Scholar
• Chitnis T , GonzalezC, HealyBCet al. Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis. Ann. Clin. Transl. Neurol., 5(12), 1478–1491 (2018).
   PubMed Web of Science ®Google Scholar
• Aktas O , RennerA, HussAet al. Serum neurofilament light chain: no clear relation to cognition and neuropsychiatric symptoms in stable MS. Neurol. Neuroimmunol. Neuroinflamm., 7(6), e885 (2020).
   PubMed Web of Science ®Google Scholar
• Kuhle J , KropshoferH, BarroCet al. The predictive value of neurofilament light chain levels in blood for cognitive impairment in patients with secondary progressive multiple sclerosis (S12.009). Neurology, 92(Suppl. 15), S12.009 (2019).
   Web of Science ®Google Scholar
• Reinert MC , BenkertP, WuerfelJet al. Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm., 7(4), e749 (2020).
   PubMed Web of Science ®Google Scholar
• Wong YYM , BruijstensAL, BarroCet al. Serum neurofilament light chain in pediatric MS and other acquired demyelinating syndromes. Neurology, 93(10), e968–e974 (2019).
   PubMed Web of Science ®Google Scholar
• Trapp BD , PetersonJ, RansohoffRM, RudickR, MorkS, BoL. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med., 338(5), 278–285 (1998).
   PubMed Web of Science ®Google Scholar
• Disanto G , BarroC, BenkertPet al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol., 81(6), 857–870 (2017).
   PubMed Web of Science ®Google Scholar
• Varhaug KN , BarroC, BjornevikKet al. Neurofilament light chain predicts disease activity in relapsing-remitting MS. Neurol. Neuroimmunol. Neuroinflamm., 5(1), e422 (2018).
   PubMed Web of Science ®Google Scholar
• Rosso M , GonzalezCT, HealyBCet al. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann. Clin. Transl. Neurol., 7(6), 945–955 (2020).
   PubMed Web of Science ®Google Scholar
• Uher T , SchaedelinS, SrpovaBet al. Monitoring of radiologic disease activity by serum neurofilaments in MS. Neurol. Neuroimmunol. Neuroinflamm., 7(4), (2020).
   PubMed Web of Science ®Google Scholar
• Uher T , MccombM, GalkinSet al. Neurofilament levels are associated with blood-brain barrier integrity, lymphocyte extravasation, and risk factors following the first demyelinating event in multiple sclerosis. Mult. Scler., 27(2),220–231 (2021).
   PubMed Web of Science ®Google Scholar
• Bergman J , DringA, ZetterbergHet al. Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS. Neurol. Neuroimmunol. Neuroinflamm., 3(5), e271 (2016).
   PubMed Web of Science ®Google Scholar
• Van Munster CE , UitdehaagBM. Outcome measures in clinical trials for multiple sclerosis. CNS Drugs, 31(3), 217–236 (2017).
   PubMed Web of Science ®Google Scholar
• Jakimovski D , KuhleJ, RamanathanMet al. Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann. Clin. Transl. Neurol., 6(9), 1757–1770 (2019).
   PubMed Web of Science ®Google Scholar
• Srpova B , UherT, HrnciarovaTet al. Serum neurofilament light chain reflects inflammation-driven neurodegeneration and predicts delayed brain volume loss in early stage of multiple sclerosis. Mult. Scler., 27(1), 52–60 (2021).
   PubMed Web of Science ®Google Scholar
• Siller N , KuhleJ, MuthuramanMet al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult. Scler., 25(5), 678–686 (2019).
   PubMed Web of Science ®Google Scholar
• Kuhle J , BarroC, DisantoGet al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult. Scler., 22(12), 1550–1559 (2016).
   PubMed Web of Science ®Google Scholar
• Jakimovski D , BergslandN, DwyerMGet al. Serum neurofilament light chain levels are associated with lower thalamic perfusion in multiple sclerosis. Diagnostics (Basel), 10(9), 685 (2020).
   PubMedGoogle Scholar
• Todea RA , LuPJ, FartariaMJet al. Evolution of cortical and white matter lesion load in early-stage multiple sclerosis: correlation with neuroaxonal damage and clinical changes. Front. Neurol., 11, 973 (2020).
   PubMed Web of Science ®Google Scholar
• Tavazzi E , BergslandN, KuhleJet al. A multimodal approach to assess the validity of atrophied T2-lesion volume as an MRI marker of disease progression in multiple sclerosis. J. Neurol., 267(3), 802–811 (2020).
   PubMed Web of Science ®Google Scholar
• Bsteh G , BerekK, HegenHet al. Serum neurofilament levels correlate with retinal nerve fiber layer thinning in multiple sclerosis. Mult. Scler., 26(13),1682–1690 (2020).
   PubMed Web of Science ®Google Scholar
• Tavazzi E , JakimovskiD, KuhleJet al. Serum neurofilament light chain and optical coherence tomography measures in MS: a longitudinal study. Neurol. Neuroimmunol. Neuroinflamm., 7(4), e737 (2020).
   PubMed Web of Science ®Google Scholar
• Kapoor R , SmithKE, AllegrettaMet al. Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology, 95(10), 436–444 (2020).
   PubMed Web of Science ®Google Scholar
• Calabresi P , KuhleJ, ArnoldDet al. Serum neurofilament light (NfL) for disease prognosis and treatment monitoring in multiple sclerosis patients: is it ready for implementation into clinical care? Mult. Scler. J. (2018). https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/231907/peter.calabresi.serum.neurofilament.light.%28nfl%29.for.disease.prognosis.and.html
   Web of Science ®Google Scholar
• Kuhle J , PlavinaT, BarroCet al. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult. Scler., 26(13), 1691–1699 (2020).
   PubMed Web of Science ®Google Scholar
• Sormani MP , HaeringDA, KropshoferHet al. Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. Ann. Clin. Transl. Neurol., 6(6), 1081–1089 (2019).
   PubMed Web of Science ®Google Scholar
• Kuhle J , KropshoferH, HaeringDAet al. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology, 92(10), e1007–e1015 (2019).
   PubMed Web of Science ®Google Scholar
• Haring DA , KropshoferH, KapposLet al. Long-term prognostic value of longitudinal measurements of blood neurofilament levels. Neurol. Neuroimmunol. Neuroinflamm., 7(5), e856 (2020).
   PubMed Web of Science ®Google Scholar
• Piehl F , KockumI, KhademiMet al. Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. Mult. Scler., 24(8), 1046–1054 (2018).
   PubMed Web of Science ®Google Scholar
• Kuhle J , KropshoferH, HaringDet al. Neurofilament light levels in the blood of patients with secondary progressive MS are higher than in primary progressive MS and may predict brain atrophy in both MS subtypes. Mult. Scler. J. (2018). https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/232039/ludwig.kappos.neurofilament.light.levels.in.the.blood.of.patients.with.html
   Google Scholar
• Kuhle J , KropshoferH, BarroCet al. Siponimod reduces neurofilament light chain blood levels in secondary progressive multiple sclerosis patients (S8.006). Neurology, 90(Suppl. 15), S8.006 (2018).
   Google Scholar
• Bar-Or A , ThaneiG, HarpCet al. Blood neurofilament light levels are lowered to a healthy donor range in patients with RMS and PPMS following ocrelizumab treatment. Mult. Scler. J. (2019). https://onlinelibrary.ectrims-congress.eu/ectrims/2019/stockholm/279451/amit.bar-or.blood.neurofilament.light.levels.are.lowered.to.a.healthy.donor.html
   Google Scholar
• Kapoor R , SellebjergF, HartungH-Pet al. Natalizumab reduces serum concentrations of neurofilament light chain in secondary progressive multiple sclerosis patients from the Phase 3 ASCEND study (S12.008). Neurology, 92(Suppl. 15), S12.008 (2019).
   Web of Science ®Google Scholar
• Hauser SL , Bar-OrA, CohenJAet al. Ofatumumab versus teriflunomide in multiple sclerosis. N. Engl. J. Med., 383(6), 546–557 (2020).
   PubMed Web of Science ®Google Scholar
• Fox R , KarafaM, KonigVet al. Effect of ibudilast on neurofilament-light chain in progressive ms: analysis from a Phase II Trial (P3.2-033). Neurology, 92(Suppl. 15), P3.2–033 (2019).
   Web of Science ®Google Scholar
• Sejbaek T , NielsenHH, PennerNet al. Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naive relapsing MS patients. J. Neurol. Neurosurg. Psychiatry, 90(12), 1324–1330 (2019).
   PubMed Web of Science ®Google Scholar
• De Flon P , LaurellK, SundstromPet al. Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial. Acta Neurol. Scand., 139(5), 462–468 (2019).
   PubMed Web of Science ®Google Scholar
• Baldassari LE , PlanchonSM, BermelRAet al. Serum neurofilament light chain concentration in a Phase I/II trial of autologous mesenchymal stem cell transplantation. Mult. Scler. J. Exp. Transl. Clin., 5(4), 2055217319887198 (2019).
   Google Scholar
• Thebault S , RTD, LeeHet al. High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS. Neurol. Neuroimmunol. Neuroinflamm., 6(5), e598 (2019).
   PubMed Web of Science ®Google Scholar
• Canto E , BarroC, ZhaoCet al. Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol., 76(11), 1359–1366 (2019).
   PubMed Web of Science ®Google Scholar
• Delcoigne B , ManouchehriniaA, BarroCet al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology, 94(11), e1201–e1212 (2020).
   PubMed Web of Science ®Google Scholar
• Novakova L , ZetterbergH, SundstromPet al. Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. Neurology, 89(22), 2230–2237 (2017).
   PubMed Web of Science ®Google Scholar
• Hyun JW , KimY, KimG, KimSH, KimHJ. Longitudinal analysis of serum neurofilament light chain: a potential therapeutic monitoring biomarker for multiple sclerosis. Mult. Scler., 26(6), 659–667 (2020).
   PubMed Web of Science ®Google Scholar
• Jakimovski D , VaughnCB, EckertS, ZivadinovR, Weinstock-GuttmanB. Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin. Drug. Saf., 19(9),1121–1142 (2020).
   PubMed Web of Science ®Google Scholar
• Akgun K , KretschmannN, HaaseRet al. Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS. Neurol. Neuroimmunol. Neuroinflamm., 6(3), e555 (2019).
   PubMed Web of Science ®Google Scholar
• Dalla Costa G , MartinelliV, MoiolaLet al. Serum neurofilaments increase at progressive multifocal leukoencephalopathy onset in natalizumab-treated multiple sclerosis patients. Ann. Neurol., 85(4), 606–610 (2019).
   PubMed Web of Science ®Google Scholar
• Khalil M , PirpamerL, HoferEet al. Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat. Commun., 11(1), 812 (2020).
   PubMed Web of Science ®Google Scholar
• Vaughn CB , JakimovskiD, KavakKSet al. Epidemiology and treatment of multiple sclerosis in elderly populations. Nat. Rev. Neurol., 15(6), 329–342 (2019).
   PubMed Web of Science ®Google Scholar
• Jakimovski D , BergslandN, DwyerMGet al. Long-standing multiple sclerosis neurodegeneration: volumetric magnetic resonance imaging comparison to Parkinson’s disease, mild cognitive impairment, Alzheimer’s disease, and elderly healthy controls. Neurobiol. Aging, 90, 84–92 (2020).
   PubMed Web of Science ®Google Scholar
• Preische O , SchultzSA, ApelAet al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat. Med., 25(2), 277–283 (2019).
   PubMed Web of Science ®Google Scholar
• Manouchehrinia A , PiehlF, HillertJet al. Confounding effect of blood volume and body mass index on blood neurofilament light chain levels. Ann. Clin. Transl. Neurol., 7(1), 139–143 (2020).
   PubMed Web of Science ®Google Scholar
• Mccomb M , ParambiR, BrowneRWet al. Apolipoproteins AI and E are associated with neuroaxonal injury to gray matter in multiple sclerosis. Mult. Scler. Relat. Disord., 45, 102389 (2020).
   PubMed Web of Science ®Google Scholar
• Mccomb M , KrikheliM, UherTet al. Neuroprotective associations of apolipoproteins A-I and A-II with neurofilament levels in early multiple sclerosis. J. Clin. Lipidol., 14(5), 675–684.e2 (2020).
   PubMed Web of Science ®Google Scholar
• Rosjo E , LindstromJC, HolmoyT, MyhrKM, VarhaugKN, TorkildsenO. Natural variation of vitamin D and neurofilament ight chain in relapsing-remitting multiple sclerosis. Front. Neurol., 11, 329 (2020).
   PubMed Web of Science ®Google Scholar
• Pape K , SteffenF, ZippF, BittnerS. Supplementary medication in multiple sclerosis: real-world experience and potential interference with neurofilament light chain measurement. Mult. Scler. J. Exp. Transl. Clin., 6(3), 2055217320936318 (2020).
   Google Scholar
• Altmann P , LeutmezerF, ZachHet al. Serum neurofilament light chain withstands delayed freezing and repeated thawing. Sci. Rep., 10(1), 19982 (2020).
   PubMed Web of Science ®Google Scholar
• Hviid CVB , KnudsenCS, ParknerT. Reference interval and preanalytical properties of serum neurofilament light chain in Scandinavian adults. Scand. J. Clin. Lab. Invest., 80(4), 291–295 (2020).
   PubMed Web of Science ®Google Scholar
• Dysinger M , MarusovG, FraserS. Quantitative analysis of four protein biomarkers: an automated microfluidic cartridge-based method and its comparison to colorimetric ELISA. J. Immunol. Methods, 451, 1–10 (2017).
   PubMed Web of Science ®Google Scholar
• Gauthier A , VielS, PerretMet al. Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament-light chain in multiple sclerosis. Ann. Clin. Transl. Neurol., 8(5), 1141–1150 (2021).
   PubMed Web of Science ®Google Scholar
• Sejbaek T , MendozaJP, PennerN, MadsenJS, OlsenDA, IllesZ. Comparison of neurofilament light chain results between two independent facilities. BMJ Neurol. Open, 2(2), e000063 (2020).
   PubMedGoogle Scholar
• Kuhle J , BarroC, HrusovskyKet al. International multi-site analytical validation of the Simoa NF-light assay in human serum samples from multiple sclerosis patients. Mult. Scler. J. (2018). https://onlinelibrary.ectrims-congress.eu/ectrims/2018/ectrims-2018/228383/jens.kuhle.international.multi-site.analytical.validation.of.the.simoa.html?f=menu=6*ce_id=1428*ot_id=20022*media=3*browseby=8
   Google Scholar
• Thebault S , BoothRA, RushCA, MacleanH, FreedmanMS. Serum neurofilament light chain measurement in MS: hurdles to clinical translation. Front. Neurosci., 15, 654942 (2021).
   PubMed Web of Science ®Google Scholar
• Freedman M , GnanapavanS. Letter to the Editor: Consensus statement on neurofilament proteins in multiple sclerosis under development by Consortium of Multiple Sclerosis Centers (CMSC) Expert Panel. Int. J. MS Care, 22(6), 294 (2020).
   PubMedGoogle Scholar